Skip to main content
Premium Trial:

Request an Annual Quote

Qiagen Leads Strong Week for BCW Index

Qiagen's shares rose 8 percent for the five-day trading period ended Tuesday, leading the 13 firms that posted gains in the BCW Index. Qiagen reported a 9-percent increase in fourth-quarter revenues on Monday after the close of the market. Its shares gained 5.4 percent in the first full day of trading after the results were released. Only three firms posted declines in their stock for the tracking period, led by Invitrogen, which fell 1.3 percent.

For the week, the Index gained 2 percent, beating out the Nasdaq, which rose .4 percent, and the Nasdaq Biotech Index, which gained .5 percent. Blue chip stocks were in favor for the week as the Dow Jones Industrial Average gained 2.6 percent.

BioCommerce Week Index of Diversified Molecular Biology Tool Companies
Company
Ticker
Current Price
(Feb. 14, 2006)
Last Price
(Feb. 7, 2006)
% change
Agilent
A
34.8
34.01
2.32
Applied Biosystems
ABI
28.29
27.8
1.76
Beckman
BEC
60.11
58.32
3.07
Bio-Rad
BIO
65.67
65.68
-0.02
Bruker
BRKR
4.58
4.62
-0.87
Fisher Scientific
FSH
68.5
66.16
3.54
GE
GE
33.46
32.31
3.56
Harvard Bio
HBIO
4.78
4.62
3.46
Invitrogen
IVGN
66
66.86
-1.29
Molecular Devices
MDCC
30.35
30.01
1.13
PerkinElmer
PKI
23.2
22.98
0.96
Qiagen
QGEN
13.18
12.2
8.03
Sigma
SIAL
64.34
63.53
1.27
Stratagene
STGN
10.65
10.12
5.24
Thermo
TMO
34.43
33.22
3.64
Waters
WAT
42.06
40.53
3.77
BCW Index Average
36.53
35.81
1.99
The Scan

Follow-Up Data Requests to Biobank Participants Ineffective, Study Finds

An effort to recontact biobank enrollees for additional information reports low participation in a new BMJ Open study.

Study Finds Widespread Transmission of Resistant Bacteria in Vietnam Hospitals

A sequencing study in The Lancet Microbe finds widespread transmission of drug-resistant Escherichia coli, Klebsiella pneumoniae, and Acinetobacter baumannii in two Vietnam ICUs.

Novel Brain Cell Organoids Show Promise for Autism Research

University of Utah researchers report in Nature Communications on their development of brain cell organoids to study SHANK3-related autism.

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.